Alejandro Ruiz-Picazo

Dr. Alejandro Ruiz-Picazo

Department of Engineering and Pharmaceutical Technology, Faculty of Pharmacy, Miguel Hernandez University, 03550 Alicante, Spain
orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 May 2018 in Molecular Pharmaceutics
Verified
Journal Article
Closed access
ARAlejandro Ruiz-Picazo
Alejandro Ruiz-Picazo
MMMª Teresa Martinez-Martinez
Mª Teresa Martinez-Martinez
SCSarin Colón-Useche
Sarin Colón-Useche
RIRamon Iriarte
Ramon Iriarte
Barbara Sanchez-DengraBarbara Sanchez-Dengra
Barbara Sanchez-Dengra
Marival BermejoMarival Bermejo
Marival Bermejo

1 April 2020 in European Journal of Pharmaceutics and Biopharmaceutics
Verified
Journal Article
Closed access
MHMichael Hofmann
Michael Hofmann
Mauricio A. GarcíaMauricio A. García
Mauricio A. García
JAJozef Al-Gousous
Jozef Al-Gousous
ARAlejandro Ruiz-Picazo
Alejandro Ruiz-Picazo
FTFlorian Thieringer
Florian Thieringer
Peter LangguthPeter Langguth
Peter Langguth

1 September 2017 in European Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
ARAlejandro Ruiz-Picazo
Alejandro Ruiz-Picazo
ILIsabel Lozoya-Agullo
Isabel Lozoya-Agullo
MOMiguel Ortiz-Azcarate
Miguel Ortiz-Azcarate
MMMatilde Merino-Sanjuán
Matilde Merino-Sanjuán
MGMarta Gonzalez-Alvarez
Marta Gonzalez-Alvarez
Marival BermejoMarival Bermejo
Marival Bermejo

1 November 2018 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
TCTamires Guedes Caldeira
Tamires Guedes Caldeira
ARAlejandro Ruiz-Picazo
Alejandro Ruiz-Picazo
ILIsabel Lozoya-Agullo
Isabel Lozoya-Agullo
DSDênia Antunes Saúde-Guimarães
Dênia Antunes Saúde-Guimarães
MGMarta Gonzalez-Alvarez
Marta Gonzalez-Alvarez
Marival BermejoMarival Bermejo
Marival Bermejo

15 March 2019 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
Marival BermejoMarival Bermejo
Marival Bermejo
GKGislaine Kuminek
Gislaine Kuminek
JAJozef Al-Gousous
Jozef Al-Gousous
ARAlejandro Ruiz-Picazo
Alejandro Ruiz-Picazo
YTYasuhiro Tsume
Yasuhiro Tsume
GAGordon L. Amidon
Gordon L. Amidon
The present work aimed to explain the differences in oral performance in fasted humans who were categorized into groups based on the three different drug product formulations of dexketoprofen trometamol (DKT) salt—Using a combination of in vitro techniques and pharmacokinetic analysis. The non-bioequivalence (non-BE) tablet group achieved higher plasma Cmax and area under the curve (AUC) than the reference and BE tablets groups, with only one difference in tablet composition, which was the presence of calcium monohydrogen phosphate, an alkalinizing excipient, in the tablet core of the non-BE formulation. Concentration profiles determined using a gastrointestinal simulator (GIS) apparatus designed with 0.01 N hydrochloric acid and 34 mM sodium chloride as the gastric medium and fasted state simulated intestinal fluids (FaSSIF-v1) as the intestinal medium showed a faster rate and a higher extent of dissolution of the non-BE product compared to the BE and reference products. These in vitro profiles mirrored the fraction doses absorbed in vivo obtained from deconvoluted plasma concentration–time profiles. However, when sodium chloride was not included in the gastric medium and phosphate buffer without bile salts and phospholipids were used as the intestinal medium, the three products exhibited nearly identical concentration profiles. Microscopic examination of DKT salt dissolution in the gastric medium containing sodium chloride identified that when calcium phosphate was present, the DKT dissolved without conversion to the less soluble free acid, which was consistent with the higher drug exposure of the non-BE formulation. In the absence of calcium phosphate, however, dexketoprofen trometamol salt dissolution began with a nano-phase formation that grew to a liquid–liquid phase separation (LLPS) and formed the less soluble free acid crystals. This phenomenon was dependent on the salt/excipient concentrations and the presence of free acid crystals in the salt phase. This work demonstrated the importance of excipients and purity of salt phase on the evolution and rate of salt disproportionation pathways. Moreover, the presented data clearly showed the usefulness of the GIS apparatus as a discriminating tool that could highlight the differences in formulation behavior when utilizing physiologically-relevant media and experimental conditions in combination with microscopy imaging.

29 May 2020 in Molecular Pharmaceutics
Verified
Journal Article
Closed access
ARAlejandro Ruiz-Picazo
Alejandro Ruiz-Picazo
MGMarta Gonzalez-Alvarez
Marta Gonzalez-Alvarez
Isabel Gonzalez-AlvarezIsabel Gonzalez-Alvarez
Isabel Gonzalez-Alvarez
Marival BermejoMarival Bermejo
Marival Bermejo